Skip NavigationSkip to Content
Return Return to Search Results

Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine

  1. Author:
    Marin, Alexander
    Chowdhury, Ananda
    Valencia, Sarah M.
    Zacharia, Athina
    Kirnbauer, Reinhard
    Roden, Richard B. S.
    Pinto,Ligia
    Shoemaker, Robert H.
    Marshall,Jason
    Andrianov, Alexander K.

  2. Author Address

    Univ Maryland, Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.Frederick Natl Lab Canc Res, Canc ImmunoPrevent Lab, Frederick, MD USA.Med Univ Vienna, Dept Dennatol, Vienna, Austria.Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.Frederick Natl Lab Canc Res, HPV Immunol Lab, Frederick, MD USA.NCI, Chemoprevent Agent Dev Res Grp, Div Canc Prevent, Rockville, MD USA.
    1. Year: 2021
    2. Date: Apr 1
  2. Journal: Nanomedicine : Nanotechnology, Biology, and Medicine
  3. ELSEVIER,
    1. 33
  5. Type of Article: Article
  6. Article Number: 102359
  7. ISSN: 1549-9634
  1. Abstract:

    Poly[di(carboxylatomethylphenoxy)phosphazene] (PCMP), a new member of polyphosphazene immunoadjuvant family, is synthesized. In vitro assessment of a new macromolecule revealed hydrolytic degradation profile and immunostimulatory activity comparable to its clinical stage homologue PCPP; however, PCMP was characterized by a beneficial reduced sensitivity to the ionic environment. In vivo evaluation of PCMP potency was conducted with human papillomavirus (HPV) virus-like particles (VLPs) based RG1-VLPs vaccine. In contrast with previously reported self-assembly of polyphosphazene adjuvants with proteins, which typically results in the formation of complexes with multimeric display of antigens, PCMP surface modified VLPs in a composition dependent pattern, which at a high polymer -to VLPs ratio led to stabilization of antigenic particles. Immunization experiments in mice demonstrated that PCMP adjuvanted RG1-VLPs vaccine induced potent humoral immune responses, in particular, on the level of highly desirable protective cross-neutralizing antibodies, and outperformed PCPP and Alhydrogel adjuvanted formulations.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.nano.2021.102359
  3. PMID: 33476764
  4. View record in Web of Science®
  5. WOS: 000657746000006

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel